Organization & Developments: Celladon

Parents

Celladon is a privately held biotechnology company founded with the goal of developing molecular therapies for cardiovascular diseases.
Developing a gene therapy/delivery device combination (administered in a cardiac catheterization laboratory) for congestive hear
First product candidate is designed to target the key enzyme deficiency in advanced heart failure which regulates calcium cycling and contractility in heart muscle cells.
Potential breakthrough for the treatment of severe heart failure. MYDICAR is designed to restore a critical enzyme necessary for the heart to pump more efficiently.